Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

139.00GBp
9 Dec 2016
Change (% chg)

1.20p (+0.87%)
Prev Close
137.80p
Open
138.20p
Day's High
139.60p
Day's Low
137.60p
Volume
1,940,477
Avg. Vol
1,849,496
52-wk High
200.10p
52-wk Low
122.90p

VEC.L

Chart for VEC.L

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Overall

Beta: 0.72
Market Cap(Mil.): £933.75
Shares Outstanding(Mil.): 677.61
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 29.74 30.35
EPS (TTM): -0.01 -- --
ROI: -2.09 15.90 15.27
ROE: -2.37 17.00 16.60

BRIEF-Vectura's first-half pretax loss widens to 18.6 million

* H1 pretax loss -18.6 million stg versus -2.7 million stg loss year ago Source text for Eikon: Further company coverage: (Reporting By London Bureau)

Nov 23 2016

BRIEF-Hikma announces U.S. deal with Vectura for generic salmeterol development

* Announces agreement with Vectura for development of generic salmeterol for U.S. market Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Nov 22 2016

Vectura on lookout for deals to build specialized lung drug business

LONDON James Ward-Lilley, the former AstraZeneca executive who created a UK respiratory medicine business in June by merging Vectura and SkyePharma, is already thinking about his next deal.

Nov 01 2016

Drugmaker Vectura raises revenue outlook on strong trading

Sept 7 Drugmaker Vectura Group Plc said it raised its revenue expectations for the nine months to Dec. 31 following strong trading to the end of August.

Sep 07 2016

Vectura's asthma therapy misses primary endpoint in final stage trial

Aug 30 Respiratory drug specialist Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a phase III trial carried out by its European partner Mundipharma.

Aug 30 2016

BRIEF-Vectura initiates legal proceedings against GSK in the U.S.

* Vectura initiates legal proceedings against GlaxoSmithKline Plc (GSK)

Jul 27 2016

BRIEF-HBM Healthcare Investments: merger of Skyepharma and Vectura effective

* Recommended all share merger of Skyepharma and Vectura becomes effective

Jun 10 2016

Earnings vs. Estimates